Lantheus Holdings Inc. (LNTH)
NASDAQ: LNTHHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LNTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.68B
- P/E (TTM)
- 25.40
- Forward P/E
- 15.34
- EPS (TTM)
- $4.02
- Dividend yield
- None
- 52-week range
- 54.94 – 111.86
- Day range
- 102.07 – 102.40
- Volume / Avg
- 1.07M / 1.02M
- Beta
- —
- Shares outstanding
- 65.40M
52-week range
LNTH stock today
Lantheus (LNTH) closed at $102.10 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. At this level, LNTH sits near the top of its 52-week range of $54.94 to $111.86: 8.7% below the high, set on Jun 30, 2026 and 85.8% above the low. LNTH is up 53.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 82.9%.
Lantheus trades at 25.4x its trailing twelve-month earnings per share of $4.02. Its forward P/E of 15.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Lantheus
Company profileLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Ms. Mary Anne Heino
- Headquarters
- Bedford, MA
- Employees
- 1,193
- IPO year
- 2015
- Website
- lantheus.com
Financial highlights
Full financialsIn fiscal 2025, Lantheus generated $1.54 billion in revenue, up 0.5% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $233.6 million (-25.2% year over year), for a net margin of 15.2% versus a median of 3.0% in the prior 5 years. Gross margin was 61.1% (down from 64.4%) and operating margin 20.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.30B | $935.06M | $425.21M |
| Growth | +0.50% | +18.32% | +38.65% | +119.91% | +25.28% |
| Net income | $233.56M | $312.44M | $326.66M | $28.07M | $-71.28M |
| EPS (diluted) | $3.41 | $4.36 | $4.65 | $0.40 | $-1.06 |
Analyst forecast
ForecastConsensus (9 analysts)
hold
Avg. price target
$105.99+3.81%
- Strong buy 1
- Buy 0
- Hold 8
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.33 vs $1.01
- Surprise
- -67.33%
LNTH news
All LNTH news- Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s DiseaseGlobeNewswire
- Lantheus Holdings, Inc. Reports Third Quarter 2026 Revenue of $389.9 millionNasdaq
- Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic RadiopharmaceuticalsGlobeNewswire
- Lantheus Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual MeetingGlobeNewswire
- Lantheus Holdings, Inc. Receives FTC Second Request Regarding MergerNasdaq
- Lantheus receives FTC second request on Curium dealSeeking Alpha
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeNasdaqGEHC, LNTH, TLX, RADX
Lantheus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORKAOruka Therapeutics Inc. | 95.81 | -1.80% | $6.50B | vs LNTH |
| NEOGNeogen Corporation | 10.55 | -2.77% | $2.30B | vs LNTH |
| CLDXCelldex Therapeutics Inc. | 27.42 | -1.93% | $2.15B | vs LNTH |
| NTLAIntellia Therapeutics Inc. | 10.00 | +5.04% | $1.40B | vs LNTH |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs LNTH |
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs LNTH |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs LNTH |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs LNTH |
Indexes, lists and sector
Lantheus stock FAQ
What is Lantheus's stock price today?
LNTH last traded at $102.10 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
What is LNTH's P/E ratio?
LNTH trades at a trailing P/E ratio of 25.40 and a forward P/E of 15.34.
Who is Lantheus's CEO?
Ms. Mary Anne Heino is the chief executive officer of Lantheus Holdings Inc., which has about 1,193 employees.
What is the LNTH 52-week high?
The 52-week high for LNTH is $111.86 and the 52-week low is $54.94. The stock is currently 8.7% below its high.